IMPORTANCE  Virus infection has been widely described as one of the most common causes of myocarditis. However, less is known about the cardiac involvement as a complication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

OBJECTIVE  To describe the presentation of acute myocardial inflammation in a patient with coronavirus disease 2019 (COVID-19) who recovered from the influenzalike syndrome and developed fatigue and signs and symptoms of heart failure a week after upper respiratory tract symptoms.

DESIGN, SETTING, AND PARTICIPANT  This case report describes an otherwise healthy 53-year-old woman who tested positive for COVID-19 and was admitted to the cardiac care unit in March 2020 for acute myopericarditis with systolic dysfunction, confirmed on cardiac magnetic resonance imaging, the week after onset of fever and dry cough due to COVID-19. The patient did not show any respiratory involvement during the clinical course.

EXPOSURE  Cardiac involvement with COVID-19.

MAIN OUTCOMES AND MEASURES  Detection of cardiac involvement with an increase in levels of N-terminal pro–brain natriuretic peptide (NT-proBNP) and high-sensitivity troponin T, echocardiography changes, and diffuse biventricular myocardial edema and late gadolinium enhancement on cardiac magnetic resonance imaging.

RESULTS  An otherwise healthy 53-year-old white woman presented to the emergency department with severe fatigue. She described fever and dry cough the week before. She was afebrile but hypotensive; electrocardiography showed diffuse ST elevation, and elevated high-sensitivity troponin T and NT-proBNP levels were detected. Findings on chest radiography were normal. There was no evidence of obstructive coronary disease on coronary angiography. Based on the COVID-19 outbreak, a nasopharyngeal swab was performed, with a positive result for SARS-CoV-2 on real-time reverse transcriptase-polymerase chain reaction assay. Cardiac magnetic resonance imaging showed increased wall thickness with diffuse biventricular hypokinesia, especially in the apical segments, and severe left ventricular dysfunction (left ventricular ejection fraction of 35%). Short tau inversion recovery and T2-mapping sequences showed marked biventricular myocardial interstitial edema, and there was also diffuse late gadolinium enhancement involving the entire biventricular wall. There was a circumferential pericardial effusion that was most notable around the right cardiac chambers. These findings were all consistent with acute myopericarditis. She was treated with dobutamine, antiviral drugs (lopinavir/ritonavir), steroids, chloroquine, and medical treatment for heart failure, with progressive clinical and instrumental stabilization.

CONCLUSIONS AND RELEVANCE  This case highlights cardiac involvement as a complication associated with COVID-19, even without symptoms and signs of interstitial pneumonia.
The first cases of coronavirus disease 2019 (COVID-19) were reported in December 2019, originating in Wuhan, China, with rapid spread worldwide, and COVID-19 became a public health emergency of international concern. The pathogen has been identified as a novel enveloped RNA beta-coronavirus and has been named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The clinical course of SARS-CoV-2 infection is mostly characterized by respiratory tract symptoms, including fever, cough, pharyngodynia, fatigue, and complications related to pneumonia and acute respiratory distress syndrome.

Data regarding cardiovascular involvement due to SARS-CoV-2 infection are less described. Previous severe acute respiratory syndrome (SARS) beta-coronavirus infections could be associated with tachyarrhythmias and signs and symptoms of heart failure. The present report describes a case of cardiac involvement in a patient affected by COVID-19. The patient provided written informed consent, and the diagnostic procedures were conducted in accordance with institutional guidelines about the protection of human subjects.

Report of a Case

An otherwise healthy 53-year-old white woman without previous history of cardiovascular disease presented to the emergency department with severe fatigue for 2 previous days. She denied chest pain, dyspnea, and further symptoms. She reported having fever and cough the week before.

On arrival to the emergency department, physical examination revealed blood pressure of 90/50 mm Hg, heart rate of 100 beats per minute, oxygen saturation of 98% while breathing ambient air, and body temperature of 36.6 °C. (She remained afebrile during the subsequent clinical course.) Arterial gas analysis showed a pH of 7.46, oxygen partial pressure of 82 mm Hg, carbon dioxide partial pressure of 32 mm Hg, lactate level of 17.1 mg/dL (to convert to millimoles per liter, multiply by 0.111). A 12-lead electrocardiogram (ECG) showed low voltage in the limb leads, minimal diffuse ST-segment elevation (more prominent in the inferior and lateral leads), and an ST-segment depression with T-wave inversion in lead V1 and aVR (Figure 1A).

Findings on chest radiography were unremarkable (Figure 1B). Blood tests revealed elevated levels of markers of myocyte necrosis (high-sensitivity troponin T level of 0.24 ng/mL [to convert to micrograms per liter, multiply by 1] and creatine kinase–MB level of 20.3 ng/mL [to convert to micrograms per liter, multiply by 1]), elevated N-terminal pro-brain natriuretic peptide (NT-proBNP) levels (5647 pg/mL [to convert to nanograms per liter, multiply by 1]), slight increase in C-reactive protein levels (1.3 mg/dL [to convert to milligrams per liter, multiply by 10]), and normal blood cell counts (Table). Blood sample tests also revealed hyperkalemia, hyponatremia, and hypochloremia. These abnormalities were treated with kayexalate, glucose and insulin solution, and sodium bicarbonate. Given the echocardiography changes, regional wall motion abnormalities, and elevated markers of

Key Points

Question What are the cardiac complications associated with the emerging outbreak of coronavirus disease 2019 (COVID-19)?

Findings In this case report, an otherwise healthy 53-year-old patient developed acute myopericarditis with systolic dysfunction confirmed on cardic magnetic resonance imaging a week after onset of fever and dry cough due to COVID-19. The patient was treated with inotropic support, antiviral drugs, corticosteroids, and chloroquine, with progressive stabilization of the clinical course.

Meaning The emerging outbreak of COVID-19 can be associated with cardiac involvement, even after the resolution of the upper respiratory tract infection.

Figure 1. Electrocardiographic and Chest Radiographic Findings

A. Electrocardiography showing sinus rhythm with low voltage in the limb leads, diffuse ST-segment elevation (especially in the inferior and lateral leads), and ST-segment depression with T-wave inversion in leads V1 and aVR. B. Posteroanterior chest radiography at presentation. No thoracic abnormalities were noted.
Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19)

Table. Clinical Laboratory Results

<table>
<thead>
<tr>
<th>Measure</th>
<th>Reference range</th>
<th>Day 1</th>
<th>Day 2</th>
<th>Day 3</th>
<th>Day 4</th>
<th>Day 5</th>
<th>Day 6</th>
<th>Day 7</th>
</tr>
</thead>
<tbody>
<tr>
<td>Red blood cell count, ×10⁶/μL</td>
<td>4.0-5.2</td>
<td>5.5⁺</td>
<td>4.6</td>
<td>4.0⁻</td>
<td>3.9⁻</td>
<td>3.8⁻</td>
<td>3.6⁻</td>
<td>3.7⁻</td>
</tr>
<tr>
<td>Hemoglobin, g/dL</td>
<td>12.0-16.0</td>
<td>17.1⁺</td>
<td>14.5</td>
<td>12.4</td>
<td>11.9⁺</td>
<td>12.0</td>
<td>11.4⁺</td>
<td>11.2⁻</td>
</tr>
<tr>
<td>Hematocrit, %</td>
<td>37.0-47.0</td>
<td>49.3⁺</td>
<td>42.1</td>
<td>36.0⁻</td>
<td>34.9⁺</td>
<td>35.1⁻</td>
<td>33.9⁺</td>
<td>33.6⁺</td>
</tr>
<tr>
<td>White blood cell count, per μL</td>
<td>4000-10 800</td>
<td>8900</td>
<td>12 090⁺</td>
<td>9920</td>
<td>10 900</td>
<td>13 470⁻</td>
<td>13 730⁺</td>
<td>13 500⁺</td>
</tr>
<tr>
<td>Lymphocyte count</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Relative, %</td>
<td>20.0-40.0</td>
<td>10.6⁻</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>7.7⁺</td>
</tr>
<tr>
<td>Absolute, per μL</td>
<td>900-4000</td>
<td>950</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>1040</td>
</tr>
<tr>
<td>Platelet count, ×10⁹/μL</td>
<td>130-400</td>
<td>152</td>
<td>168</td>
<td>164</td>
<td>213</td>
<td>317</td>
<td>317</td>
<td>360</td>
</tr>
<tr>
<td>Sodium, mEq/L</td>
<td>136-145</td>
<td>129⁺</td>
<td>133⁻</td>
<td>129⁺</td>
<td>136</td>
<td>132⁻</td>
<td>134⁻</td>
<td>137</td>
</tr>
<tr>
<td>Potassium, mEq/L</td>
<td>3.4-4.5</td>
<td>5.7⁺</td>
<td>6.3⁺</td>
<td>3.9</td>
<td>3.7</td>
<td>3.5</td>
<td>3.6</td>
<td>3.6</td>
</tr>
<tr>
<td>Chloride, mEq/L</td>
<td>98-107</td>
<td>89⁺</td>
<td>96⁺</td>
<td>92⁺</td>
<td>92⁺</td>
<td>NA</td>
<td>92⁺</td>
<td>94⁺</td>
</tr>
<tr>
<td>Calcium, mg/dL</td>
<td>8.60-10.20</td>
<td>8.63</td>
<td>NA</td>
<td>7.84⁺</td>
<td>8.15⁻</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Creatinine, mg/dL</td>
<td>0.60-1.00</td>
<td>0.75</td>
<td>0.76</td>
<td>0.53⁺</td>
<td>0.88</td>
<td>0.99</td>
<td>0.96</td>
<td>0.80</td>
</tr>
<tr>
<td>C-reactive protein, mg/dL</td>
<td>&lt;0.5</td>
<td>1.3⁺</td>
<td>0.7⁺</td>
<td>1.0⁺</td>
<td>1.1⁺</td>
<td>0.6</td>
<td>0.4⁺</td>
<td>0.3⁺</td>
</tr>
<tr>
<td>Creatine kinase–MB, ng/mL</td>
<td>&lt;4.9</td>
<td>20.3⁺</td>
<td>39.9⁺</td>
<td>30.7⁺</td>
<td>13.3⁺</td>
<td>5.2</td>
<td>3.3⁺</td>
<td>2.8⁺</td>
</tr>
<tr>
<td>High-sensitivity troponin T, ng/mL</td>
<td>&lt;0.01</td>
<td>0.24</td>
<td>0.59</td>
<td>0.78</td>
<td>0.89</td>
<td>0.76⁺</td>
<td>0.65⁺</td>
<td>0.63⁺</td>
</tr>
<tr>
<td>NT-proBNP, pg/mL</td>
<td>&lt;300⁺</td>
<td>5647</td>
<td>8465</td>
<td>8133</td>
<td>5113</td>
<td>2827</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>

Abbreviations: NA, not applicable; NT-proBNP, N-terminal pro–brain natriuretic peptide.

SI conversion factors: To convert red blood cell count to ×10⁶ per liter, multiply by 1; hemoglobin to grams per liter, multiply by 10; white blood cell count to ×10⁹ per liter, multiply by 1; sodium to millimoles per liter, multiply by 1; potassium to millimoles per liter, multiply by 1; chloride to millimoles per liter, multiply by 1; C-reactive protein to milligrams per liter, multiply by 1; creatine kinase–MB to micrograms per liter, multiply by 1; high-sensitivity troponin T to micrograms per liter, multiply by 1; and NT-proBNP to nanograms per liter, multiply by 1.

© 2020 American Medical Association. All rights reserved.

myocardial necrosis, urgent coronary angiography was performed, which showed no evidence of obstructive coronary disease.

The patient was admitted to the intensive care unit with a diagnosis of suspected myopericarditis. Based on the clinical history and the COVID-19 outbreak, COVID-19 was deemed as likely. A nasopharyngeal swab was performed with a positive result for SARS-CoV-2 on real-time reverse transcriptase-polymerase chain reaction assay. Search for common cardiotoxic infectious agents yielded negative results.

Transthoracic echocardiography revealed normal left ventricular (LV) dimensions with an increased wall thickness (interventricular septum, 14 mm, posterior wall, 14 mm) and a diffuse echo-bright appearance of the myocardium. There was diffuse hypokinesis, with an estimated LV ejection fraction (LVEF) of 40%. There was no evidence of heart valvedisease.

During the first days of her hospitalization, the patient remained hypotensive (systolic blood pressure less than 90 mm Hg) and required inotropic support (dobutamine) in the first 48 hours, during which there was a further increase in levels of NT-proBNP (8465 pg/mL), high-sensitivity troponin T (0.59 ng/mL), and creatine kinase–MB (39.9 ng/mL), with a progressive stabilization and reduction during the following days (Table). Blood pressure progressively stabilized, although systolic pressure remained less than 100 mm Hg, and dobutamine treatment was weaned on day 4. Heart failure–directed medical treatment was started with daily doses of 50 mg of kanrenone, 25 to 50 mg of furosemide, and 2.5 mg of bisoprolol, then reduced and finally withdrawn on day 5 owing to sinus bradycardia. The patient was treated on admission with intravenous aspirin (500 mg twice daily), and given the cardiac MRI findings, hydroxychloroquine (200 mg twice daily), lopinavir/ritonavir (2 tablets of 200/50 mg twice daily), and intravenous methylprednisolone (1 mg/kg daily for 3 days) were administrated. Chest radiography was repeated on day 4 and showed no thoracic abnormalities. Transthoracic echocardiography, performed on day 6, revealed a significant reduction of LV wall thickness (interventricular septum, 11 mm; pos-
terior wall, 10 mm), an improvement of LVEF to 44%, and a slight decrease of pericardial effusion (maximum, 8-9 mm). At the time of submission, the patient was hospitalized with progressive clinical and hemodynamic improvement.

Discussion

Herein, we describe a patient without a history of cardiovascular disease admitted to the hospital with COVID-19 and severe LV dysfunction and acute myopericarditis. Our main findings are that cardiac involvement may occur with COVID-19 even without respiratory tract signs and symptoms of infection.

After the first cases describing pneumonia cases of unknown origin in Wuhan, China, SARS-CoV-2 rapidly spread worldwide with critical challenges for the public health and medical communities.1,2 The World Health Organization has declared SARS-CoV-2 a public health emergency of international concern, with a global estimate of 98,192 laboratory-confirmed cases and 3,380 deaths as of March 6, 2020.

A 2020 report by the China Medical Treatment Expert Group for COVID-199 showed the spectrum of clinical and diagnostic features associated with SARS-CoV-2 infection among
Chinese patients. The most common symptoms were fever (in up to 88.7% of patients during hospitalization) and cough (in 67.8% of patients), followed by dry cough, headache, fatigue, or shortness of breath. Complications were mostly related to physician-diagnosed pneumonia (91.1%) and acute respiratory distress syndrome.3,4 While the spectrum of clinical manifestation is highly related to the inflammation process of the respiratory tract, this case provides evidence of cardiac involvement as a possible late phenomenon of the viral respiratory infection. This process can be subclinical with few interstitial inflammatory cells, as reported by an autopsy study,10 or can present with overt manifestations even without respiratory symptoms, as in the present case.

Virus infection has been widely described as one of the most common infectious causes of myocarditis, especially associated with influenza and parvovirus B-19 infection.11 However, less is known about the cardiac involvement as a complication of SARS-CoV-2 infection.

Myocarditis results in focal or global myocardial inflammation, necrosis, and eventually ventricular dysfunction. Focal myocarditis is often suspected in patients presenting with chest pain after an influenza-like syndrome, with clinical evidence suggesting an acute coronary syndrome on electrocardiography or laboratory testing or with evidence of wall motion abnormalities without evidence of obstructive coronary artery disease on coronary angiography.12

The pathogenesis of cardiac involvement associated with SARS-CoV-2 may reflect a process of replication and dissemination of the virus through the blood or the lymphatic system from the respiratory tract. However, to our knowledge, there are no reports of influenza virus or coronavirus RNA in the heart, to date. Alternatively, SARS-CoV-2 could trigger an exaggerated inflammatory response that can cause myocardial injury, and this could justify the use of corticosteroids to attenuate inflammation, as in the present case. Evidence of a significant inflammatory cell infiltration has been reported in the alveoli of patients with acute respiratory distress syndrome associated with SARS-CoV-2 infection,10 and this could explain the use of corticosteroids in patients with COVID-19 (up to 58% in a series of critically ill patients13). Although ultrastructural mechanisms are not certain, a potential binding to a viral receptor of the myocyte can favor the internalization and subsequent replication of the capsid proteins and the viral genome.14,15 In this patient, increases of cardiac troponin levels as a sensitive marker of myocardial injury, the cardiac MRI findings showing diffuse edema, and the slow gadolinium washout are in line with an acute myocarditis. In addition, the onset of symptoms several days after the influenza-like syndrome may reflect these proposed mechanisms with a potential myocyte dissemination of the virus, the activation of the immune system, and, ultimately, the clinical onset of heart failure.

Limitations

As endomyocardial biopsy was not performed, limitations of this report are the lack of the histological demonstration of myocarditis and the absence of viral genome search in the heart. Except for the first 48 hours during which she required inotropic support, the patient was mainly treated with heart failure–directed medical treatment. However, as described in the literature, viral myocarditis has a wide spectrum of clinical presentations, ranging from life-threatening arrhythmias to advanced heart failure requiring invasive support.10

Conclusions

We believe that recognition by the scientific community of acute myocarditis as a possible complication associated with COVID-19 may be helpful for strict monitoring of affected patients and also for furthering knowledge of such complications for public health officials. This report highlights the importance of clinical surveillance and laboratory testing, including troponin levels, in individuals with recent symptoms of an acute illness to guarantee appropriate identification and prompt isolation of patients at risk of COVID-19 and eventually to reduce further transmission. Further evidence is needed to determine whether corticosteroids are useful in reducing the myocardial inflammatory response. We cannot exclude that a spontaneous resolution occurred or that antiviral drugs or chloroquine contributed to the improvement of this patient. Finally, awareness of atypical presentations such as this one is important to prompt patient isolation and prevent interhuman transmission.

REFERENCES


ARTICLE INFORMATION

Accepted for Publication: March 13, 2020.
Published Online: March 27, 2020.

Author Contributions: Drs Inciardi and Metra had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Inciardi, Lupi, Zacccone, Italy, Raffo, Tomasoni, Cani, Maroldi, Sinagra, Lombardi, Metra.

Acquisition, analysis, or interpretation of data: Inciardi, Lupi, Zacccone, Raffo, Cerini, Farina, Gavazzi, Adamo, Ammirati, Metra.

Drafting of the manuscript: Inciardi, Lupi, Zacccone, Raffo, Cerini, Farina, Gavazzi, Adamo, Ammirati, Metra.

Critical revision of the manuscript for important intellectual content: Inciardi, Lupi, Cerini, Gavazzi, Maroldi, Adamo, Ammirati, Sinagra, Lombardi, Metra.

Administrative, technical, or material support: Lupi, Cerini, Metra.

Study supervision: Inciardi, Lupi, Farina, Maroldi, Adamo, Ammirati, Sinagra, Metra.

Conflict of Interest Disclosures: Dr Farina has received personal fees from Bayer and Bracco Group. Dr Metra has received personal fees from Abbott Vascular, Amgen, Bayer, Edwards Therapeutics, and Vifor Pharma. No other disclosures were reported.

Additional Contributions: We thank the patient for granting permission to publish this information.

© 2020 American Medical Association. All rights reserved.


15. Liu PP, Mason JW. Advances in the understanding of myocarditis. Circulation. 2001;104(9):1076-1082. doi:10.1161/01.CIR.3401.095198